Literature DB >> 24853691

Declining childhood and adolescent cancer mortality.

Malcolm A Smith1, Sean F Altekruse, Peter C Adamson, Gregory H Reaman, Nita L Seibel.   

Abstract

BACKGROUND: To evaluate whether progress continues in identifying more effective treatments for children and adolescents with cancer, the authors examined both overall and disease-specific childhood cancer mortality rates for the United States, focusing on data from 2000 to 2010.
METHODS: Age-adjusted US mortality trends from 1975 to 2010 were estimated using joinpoint regression analysis. Analyses of annual percentage change (APC) were performed on the same diagnostic groupings for the period restricted to 2000 through 2010 for groupings ages <20 years, <15 years, and 15 to 19 years.
RESULTS: After a plateau in mortality rates during 1998 to 2002 (APC, 0.3%), the annual decline in childhood cancer mortality from 2002 to 2010 (APC, -2.4%) was similar to that observed from 1975 to 1998 (APC, -2.7%). Statistically significant declines in mortality rates from 2000 to 2010 were noted for acute lymphoblastic leukemia, acute myeloid leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, neuroblastoma, central nervous system cancers, and gonadal cancers. From 2000 to 2010, the rates of decline in mortality for the group ages 15 to 19 years generally were equal to or greater than the rates of decline for the group ages birth to 14 years. Improvements in treatment since 1975 resulted >45,000 cancer deaths averted through 2010.
CONCLUSIONS: Cancer mortality for both children and adolescents declined from 2000 to 2010, with significant declines observed for multiple cancer types. However, greater than 1900 cancer deaths still occur each year among children and adolescents in the United States, and many survivors experience long-term effects that limit their quality of life. Continued research directed toward identifying more effective treatments that produce fewer long-term sequelae is critical to address these remaining challenges. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  adolescents; childhood cancer; childhood leukemia; childhood solid tumors; mortality rates

Mesh:

Year:  2014        PMID: 24853691      PMCID: PMC4136455          DOI: 10.1002/cncr.28748

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Authors:  Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

Review 2.  Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.

Authors:  Hagop Kantarjian; Deborah Thomas; Alan S Wayne; Susan O'Brien
Journal:  J Clin Oncol       Date:  2012-08-13       Impact factor: 44.544

3.  Population survival from childhood cancer in Britain during 1978-2005 by eras of entry to clinical trials.

Authors:  C A Stiller; M E Kroll; K Pritchard-Jones
Journal:  Ann Oncol       Date:  2012-07-17       Impact factor: 32.976

4.  Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Yousif Matloub; Bruce C Bostrom; Stephen P Hunger; Linda C Stork; Anne Angiolillo; Harland Sather; Mei La; Julie M Gastier-Foster; Nyla A Heerema; Scott Sailer; Patrick J Buckley; Blythe Thomson; Catherine Cole; James B Nachman; Gregory Reaman; Naomi Winick; William L Carroll; Meenakshi Devidas; Paul S Gaynon
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

5.  All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).

Authors:  Harry J Iland; Ken Bradstock; Shane G Supple; Alberto Catalano; Marnie Collins; Mark Hertzberg; Peter Browett; Andrew Grigg; Frank Firkin; Amanda Hugman; John Reynolds; Juliana Di Iulio; Campbell Tiley; Kerry Taylor; Robin Filshie; Michael Seldon; John Taper; Jeff Szer; John Moore; John Bashford; John F Seymour
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

6.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

Authors:  Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

7.  Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.

Authors:  Margaret J Dougherty; Mariarita Santi; Marcia S Brose; Changqing Ma; Adam C Resnick; Angela J Sievert; Phillip B Storm; Jaclyn A Biegel
Journal:  Neuro Oncol       Date:  2010-02-14       Impact factor: 12.300

8.  Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Nita L Seibel; Peter G Steinherz; Harland N Sather; James B Nachman; Cynthia Delaat; Lawrence J Ettinger; David R Freyer; Leonard A Mattano; Caroline A Hastings; Charles M Rubin; Kathy Bertolone; Janet L Franklin; Nyla A Heerema; Torrey L Mitchell; Allan F Pyesmany; Mei K La; Cheryl Edens; Paul S Gaynon
Journal:  Blood       Date:  2007-11-26       Impact factor: 22.113

9.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

10.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.

Authors:  Kirk R Schultz; W Paul Bowman; Alexander Aledo; William B Slayton; Harland Sather; Meenakshi Devidas; Chenguang Wang; Stella M Davies; Paul S Gaynon; Michael Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew Carroll; Nyla A Heerema; Naomi Winick; Michael J Borowitz; Stephen P Hunger; William L Carroll; Bruce Camitta
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

View more
  149 in total

1.  Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Authors:  Fjoralba Zeka; Anneleen Decock; Alan Van Goethem; Katrien Vanderheyden; Fleur Demuynck; Tim Lammens; Hetty H Helsmoortel; Joëlle Vermeulen; Rosa Noguera; Ana P Berbegall; Valérie Combaret; Gudrun Schleiermacher; Geneviève Laureys; Alexander Schramm; Johannes H Schulte; Sven Rahmann; Julie Bienertová-Vašků; Pavel Mazánek; Marta Jeison; Shifra Ash; Michael D Hogarty; Mirthala Moreno-Smith; Eveline Barbieri; Jason Shohet; Frank Berthold; Tom Van Maerken; Frank Speleman; Matthias Fischer; Katleen De Preter; Pieter Mestdagh; Jo Vandesompele
Journal:  JCI Insight       Date:  2018-12-06

2.  Obesity and Metabolic Disease After Childhood Cancer.

Authors:  Dana Barnea; Nirupa Raghunathan; Danielle Novetsky Friedman; Emily S Tonorezos
Journal:  Oncology (Williston Park)       Date:  2015-11       Impact factor: 2.990

3.  Cost-effectiveness of levofloxacin prophylaxis against bacterial infection in pediatric patients with acute myeloid leukemia.

Authors:  Meghan McCormick; Erika Friehling; Ramasubramanian Kalpatthi; Nalyn Siripong; Kenneth Smith
Journal:  Pediatr Blood Cancer       Date:  2020-07-25       Impact factor: 3.167

4.  Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.

Authors:  Sara M Federico; Kenneth J Caldwell; Mary B McCarville; Vinay M Daryani; Clinton F Stewart; Shenghua Mao; Jianrong Wu; Andrew M Davidoff; Victor M Santana; Wayne L Furman; Alberto S Pappo; Fariba Navid
Journal:  Eur J Cancer       Date:  2020-04-20       Impact factor: 9.162

5.  Predictors of Success of Phase II Pediatric Oncology Clinical Trials.

Authors:  Laura Franshaw; Maria Tsoli; Jennifer Byrne; Chelsea Mayoh; Siva Sivarajasingam; Murray Norris; Glenn M Marshall; David S Ziegler
Journal:  Oncologist       Date:  2019-02-26

6.  Parental Considerations Regarding Cure and Late Effects for Children With Cancer.

Authors:  Katie A Greenzang; Hasan Al-Sayegh; Clement Ma; Mehdi Najafzadeh; Eve Wittenberg; Jennifer W Mack
Journal:  Pediatrics       Date:  2020-04-13       Impact factor: 7.124

7.  Parental distress and desire for information regarding long-term implications of pediatric cancer treatment.

Authors:  Katie A Greenzang; Angel M Cronin; Tammy I Kang; Jennifer W Mack
Journal:  Cancer       Date:  2018-10-01       Impact factor: 6.860

8.  NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.

Authors:  Francesco Marampon; Silvia Codenotti; Francesca Megiorni; Andrea Del Fattore; Simona Camero; Giovanni Luca Gravina; Claudio Festuccia; Daniela Musio; Francesca De Felice; Valerio Nardone; Anna Natalizia Santoro; Carlo Dominici; Alessandro Fanzani; Luigi Pirtoli; Antonella Fioravanti; Vincenzo Tombolini; Sara Cheleschi; Paolo Tini
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-30       Impact factor: 4.553

9.  The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma.

Authors:  Narendra Bharathy; Noah E Berlow; Eric Wang; Jinu Abraham; Teagan P Settelmeyer; Jody E Hooper; Matthew N Svalina; Yoshihiro Ishikawa; Keith Zientek; Zia Bajwa; Martin W Goros; Brian S Hernandez; Johannes E Wolff; Michelle A Rudek; Linping Xu; Nicole M Anders; Ranadip Pal; Alexandria P Harrold; Angela M Davies; Arya Ashok; Darnell Bushby; Maria Mancini; Christopher Noakes; Neal C Goodwin; Peter Ordentlich; James Keck; Douglas S Hawkins; Erin R Rudzinski; Bishwanath Chatterjee; Hans Peter Bächinger; Frederic G Barr; Jennifer Liddle; Benjamin A Garcia; Atiya Mansoor; Theodore J Perkins; Christopher R Vakoc; Joel E Michalek; Charles Keller
Journal:  Sci Signal       Date:  2018-11-20       Impact factor: 8.192

Review 10.  Identifying novel therapeutic agents using xenograft models of pediatric cancer.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-18       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.